AnaptysBio Inc (NASDAQ:ANAB) has received a consensus recommendation of “Hold” from the twelve research firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $64.17.
A number of research analysts have recently issued reports on the company. ValuEngine upgraded AnaptysBio from a “hold” rating to a “buy” rating in a research report on Friday, August 16th. Credit Suisse Group decreased their target price on AnaptysBio from $75.00 to $48.00 and set a “neutral” rating on the stock in a research report on Thursday, October 3rd. SunTrust Banks lowered AnaptysBio from a “buy” rating to a “hold” rating in a research report on Friday. Zacks Investment Research upgraded AnaptysBio from a “hold” rating to a “buy” rating and set a $42.00 target price on the stock in a research report on Wednesday, October 30th. Finally, Guggenheim lowered AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Friday.
A number of hedge funds and other institutional investors have recently bought and sold shares of ANAB. Invesco Ltd. raised its stake in AnaptysBio by 25,030.8% in the 2nd quarter. Invesco Ltd. now owns 1,097,462 shares of the biotechnology company’s stock valued at $61,919,000 after purchasing an additional 1,093,095 shares during the last quarter. BlackRock Inc. raised its stake in AnaptysBio by 13.4% in the 2nd quarter. BlackRock Inc. now owns 2,050,390 shares of the biotechnology company’s stock valued at $115,681,000 after purchasing an additional 242,187 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in AnaptysBio by 18.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 937,273 shares of the biotechnology company’s stock valued at $52,881,000 after purchasing an additional 147,292 shares during the last quarter. Nuveen Asset Management LLC acquired a new position in AnaptysBio in the 2nd quarter valued at $5,606,000. Finally, Jennison Associates LLC raised its stake in AnaptysBio by 68.5% in the 2nd quarter. Jennison Associates LLC now owns 162,422 shares of the biotechnology company’s stock valued at $9,164,000 after purchasing an additional 66,031 shares during the last quarter.
Shares of ANAB traded down $25.98 during mid-day trading on Thursday, hitting $10.18. 17,702,700 shares of the company traded hands, compared to its average volume of 366,688. AnaptysBio has a 1-year low of $10.00 and a 1-year high of $83.10. The company has a market capitalization of $1.05 billion, a PE ratio of -4.07 and a beta of 1.50. The business has a 50 day moving average of $36.21 and a 200 day moving average of $53.30.
AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Friday, November 8th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.06). During the same quarter in the previous year, the firm posted ($0.66) earnings per share. On average, sell-side analysts predict that AnaptysBio will post -4.02 earnings per share for the current fiscal year.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
See Also: Technical Analysis
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.